Haw Par Corporation Ltd banner

Haw Par Corporation Ltd
SGX:H02

Watchlist Manager
Haw Par Corporation Ltd Logo
Haw Par Corporation Ltd
SGX:H02
Watchlist
Price: 17.21 SGD 0.29% Market Closed
Market Cap: S$3.8B

EV/GP

23.8
Current
43%
More Expensive
vs 3-y average of 16.6

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
23.8
=
Enterprise Value
S$3.2B
/
Gross Profit
S$128.8m

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
23.8
=
Enterprise Value
S$3.2B
/
Gross Profit
S$128.8m

Valuation Scenarios

Haw Par Corporation Ltd is trading above its 3-year average

If EV/GP returns to its 3-Year Average (16.6), the stock would be worth S$12.03 (30% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-75%
Maximum Upside
No Upside Scenarios
Average Downside
35%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 23.8 S$17.21
0%
3-Year Average 16.6 S$12.03
-30%
5-Year Average 18.1 S$13.08
-24%
Industry Average 21.2 S$15.31
-11%
Country Average 5.9 S$4.28
-75%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
SG
Haw Par Corporation Ltd
SGX:H02
3.8B SGD 23.8 14.4
US
Eli Lilly and Co
NYSE:LLY
883B USD 16.9 42.8
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 8.8 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 6.3 20.1
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 6.4 28
US
Merck & Co Inc
NYSE:MRK
270.2B USD 5.7 14.8
CH
Novartis AG
SIX:NOVN
216.3B CHF 7.4 20.7
IE
Endo International PLC
LSE:0Y5F
244.4B USD 160.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 5.2 11.8
US
Pfizer Inc
NYSE:PFE
151.8B USD 4.2 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 4.4 17.3
P/E Multiple
Earnings Growth PEG
SG
Haw Par Corporation Ltd
SGX:H02
Average P/E: 21.6
14.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.8
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.3
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
US
Merck & Co Inc
NYSE:MRK
14.8
14%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.5
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1

Market Distribution

Higher than 90% of companies in Singapore
Percentile
90th
Based on 496 companies
90th percentile
23.8
Low
0 — 2.6
Typical Range
2.6 — 10.3
High
10.3 —
Distribution Statistics
Singapore
Min 0
30th Percentile 2.6
Median 5.9
70th Percentile 10.3
Max 26 151.2

Haw Par Corporation Ltd
Glance View

Market Cap
3.8B SGD
Industry
Pharmaceuticals

In the vibrant tapestry of Southeast Asian business, Haw Par Corporation Ltd. stands out as a unique blend of both tradition and innovation. Emerging from its roots as a family business founded in 1969, the company has grown into a diversified conglomerate, best known for its iconic Tiger Balm brand. Originally developed as a remedy inspired by ancient Chinese herbal medicine, Tiger Balm has evolved into a global household name. This tiny jar of relief epitomizes Haw Par’s ability to mesh cultural heritage with contemporary needs, capturing a significant share of the health and wellness market worldwide. The brand's entrenched position in the personal care sector, coupled with effective distribution networks and marketing strategies, ensures a steady stream of revenue flowing from markets across Asia, Europe, and the Americas. Beyond the allure of Tiger Balm, Haw Par's business model is strategically diversified. The company has smartly ventured into the fields of leisure and hospitality, healthcare investments, and property management. This diversification is a calculated play to mitigate risks associated with over-reliance on a single revenue stream. Their leisure segment features iconic attractions in Singapore, while their property holdings include high-value real estate that generates steady rental income. Additionally, Haw Par’s portfolio is anchored by substantial strategic investments in blue-chip stocks across the region, ensuring it partakes in the economic prosperity of Asia. Together, these well-curated ventures have created a robust financial ecosystem within the company, allowing it to maintain resilience in the face of economic fluctuations and to consistently drive shareholder value.

H02 Intrinsic Value
10.6 SGD
Overvaluation 38%
Intrinsic Value
Price S$17.21
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett